Latest:
Dr. Quinn on the Future of Treatments for RCC
David I. Quinn, MD, MBBS, associate professor of Medicine, medical director of USC Norris Cancer Hospital, on the future of treatments for patients with renal cell carcinoma (RCC).
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
David J. Andorsky, MD
Latest:
Dr Andorsky on Real-World Treatment Patterns With BTK Inhibitors in CLL/SLL
David J. Andorsky, MD, discusses recently observed patterns of care with BTK inhibitors in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in the community setting in the United States, and how social determinants of health may have affected these outcomes.
David J. Einstein, MD
Latest:
Dr. Einstein on Treatment Approaches in Early Oligometastatic Prostate Cancer
David J. Einstein, MD, instructor of medicine, Harvard Medical School, attending physician, Beth Israel Deaconess Medical Center, discusses treatment approaches for patients with early evidence of oligometastatic prostate cancer.
David J. Straus, MD
Latest:
Dr. Straus on the 3-Year Results of the ECHELON-1 Study in Hodgkin Lymphoma
David J. Straus, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the 3-year follow-up results of the ECHELON-1 study, which examines brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma.
David Korones, MD
Latest:
(Never) A Typical Day in the Life of a Pediatric Hematologist/Oncologist
There is no such thing as a typical day. Our days are punctuated by the unexpected and our field is so diverse that we often change what we do over the course of our careers. Time alters us and our field.
David L. Rimm, MD, PhD
Latest:
Dr. David L. Rimm on the Continued Role for PD-L1 Testing in NSCLC
David L. Rimm, MD, PhD, professor of pathology and of medicine, director of pathology tissue services, director of translational pathology, Yale Cancer Center, discusses the continued role for PD-L1 testing to predict response with checkpoint inhibitors in non­–small cell lung cancer (NSCLC).
David M. Jackman
Latest:
Dr. Jackman on Benefits of Liquid Biopsies in Lung Cancer
David M. Jackman, MD, medical director of Clinical Pathways, Dana-Farber Cancer Institute, assistant professor of Medicine, Harvard Medical School, discusses the benefits of liquid biopsies for patients with lung cancer.